Embolization of the middle meningeal artery for chronic subdural hematoma: The OTEMACS multicenter, randomized, clinical trial protocol.

ABSTRACT: BackgroundThe role of middle meningeal artery (MMA) embolization as an adjunct to standard treatment in chronic subdural hematoma (CSDH) is debated. Further randomized trials are needed to establish MMA embolization as an essential therapeutic option for CSDH. The OTEMACS study aims to assess the adjunctive benefit of MMA embolization in patients undergoing either conservative or surgical treatment for CSDH.MethodsOTEMACS is a multicenter, prospective, randomized controlled clinical trial with an open-label and blinded endpoint evaluation (PROBE) design. Patients with symptomatic CSDH treated either with conservative or surgical treatment are randomized 1:1 to receive MMA embolization within 72 h (experimental arm) or standard of care alone (control arm). The primary efficacy outcome is a

SUBMITTER: Ng S 

PROVIDER: S-EPMC12237945 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature